- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04916132
Diabetic Nephropathy in People With Diabetes. Prevalence and Predictive Factors (PRIMETIME2)
Biopsy-proven Diabetic Nephropathy in People With Type 2 Diabetes. Prevalence and Predictive Factors
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The PRIMETIME project is made to bring together molecular, translational and clinical scientists to create collaborations and build a scientific bridge between diabetology, nephrology, clinical biochemistry, and pathology. The ultimately goal is to bring forward an improved understanding of the most frequent cause of end stage renal disease: DKD. We aim to improve the diagnostic accuracy as well as the treatment precision by investigating in detail the features of histology and protein expression in both retrospective(WP1) and prospective(WP2) kidney biopsy material.
PRIMETIME WP2 is a prospective, observational, multi-center study with a cohort of 300 patients. We plan to create a systematically unselected cohort of patients with Type2 diabetes and macroalbuminuria as a sign of kidney injury. Prospectively we will collect research kidney biopsies and other biomarkers from blood, faeces, urine, proteomic- and metabolomic profiles and DNA-variants. The biopsies will be thoroughly investigated with cutting-edge molecular technologies and associated to the biomarkers, disease course and clinical outcome. The participants will afterward be followed in 20 years.Thereby we hope to be able to discover molecular and clinical profiles, that can help us in the diagnosis of DKD, and to identify different risks of progression that can benefit from different forms of personalized treatment.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Ditte Hansen
- Phone Number: +4538682056
- Email: ditte.hansen.04@regionh.dk
Study Contact Backup
- Name: Marie Møller
- Phone Number: +4561695364
- Email: marie.moeller@regionh.dk
Study Locations
-
-
-
Aalborg, Denmark
- Recruiting
- Aalborg Universitetshospital
-
Contact:
- Charlotte Strandhave, MD PhD
-
Contact:
- Peter Vestergaard
-
Gødstrup, Denmark
- Recruiting
- Regionshospitalet Gødstrup
-
Contact:
- Frank H Mose
-
Herlev, Denmark, 2730
- Recruiting
- Herlev Hospital
-
Contact:
- Ditte Hansen, MD, PhD
- Phone Number: +4538682056
- Email: ditte.hansen.04@regionh.dk
-
Contact:
- Marie Møller, MD
- Phone Number: +4561695364
- Email: marie.moeller@regionh.dk
-
Sub-Investigator:
- Iain Bressendorff, MD, PhD
-
Sub-Investigator:
- Bo Broberg, MD
-
Hillerød, Denmark, 3400
- Recruiting
- Kristine D Schandorff
-
Contact:
- Kristine D Schandorff, MD
- Email: kristine.dyhr.schandorff@regionh.dk
-
Contact:
- Signe SS Rasmussen, MD, PhD
- Email: signe.sabine.saetre.rasmussen@regionh.dk
-
Holbæk, Denmark, 4300
- Recruiting
- Holbæk Hospital
-
Contact:
- Morten Lindhardt, MD, PhD
- Email: moli@regionsjaelland.dk
-
Contact:
- Jesper O Christensen, MD, PhD
- Email: joc@regionsjaelland.dk
-
Køge, Denmark, 4600
- Recruiting
- Sjællands Universitetshospital, Køge
-
Contact:
- Urd L Kielgast, MD, PhD
- Email: ulki@regionsjaelland.dk
-
Odense, Denmark
- Recruiting
- Odense Universitetshospital
-
Contact:
- Karoline Schousboe
-
Roskilde, Denmark, 4000
- Recruiting
- Sjællands Universitetshospital, Roskilde
-
Contact:
- Rikke Borg, MD, PhD
- Phone Number: +4530223200
- Email: rbor@regionsjaelland.dk
-
Contact:
- Karina H Jensen, MD
- Email: khr@regionsjaelland.dk
-
Sub-Investigator:
- Bjarne Ørskov, MD, PhD
-
Slagelse, Denmark, 4200
- Recruiting
- Slagelse Sygehus
-
Contact:
- Eva M Lerche-Black, MD, PhD
- Email: emle@regionsjaelland.dk
-
-
Aarhus
-
Skejby, Aarhus, Denmark, 8200
- Recruiting
- Aarhus Universitetshospital, Skejby
-
Contact:
- Johan V Povlsen, MD, PhD
- Email: johan.povlsen@skejby.rm.dk
-
Contact:
- Søren T Knudsen
- Email: soerknud@rm.dk
-
-
Gentofte
-
Copenhagen, Gentofte, Denmark, 2820
- Recruiting
- Steno Diabetes Center Copenhagen
-
Contact:
- Peter C Rossing, MD,PHD, PROF
- Email: peter.rossing@regionh.dk
-
Contact:
- Frederik Persson, MD, MDSc
- Phone Number: +4527512622
- Email: frederik.persson@regionh.dk
-
-
København Ø
-
Copenhagen, København Ø, Denmark, 2100
- Recruiting
- Rigshospitalet
-
Contact:
- Mads Copenhagen, MD, PhD
- Email: mads.hornum@regionh.dk
-
Contact:
- Thomas Almdal, MD, MDSc
-
-
Nykøbing F
-
Nykøbing Falster, Nykøbing F, Denmark, 4800
- Recruiting
- Nykøbing Falster Sygehus
-
Contact:
- Allan Kofoed-Enevoldsen, MD
- Email: akofo@regionsjaelland.dk
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age ≥ 18 years
- Written informed consent
- Diagnosis with T2DM according to the American diabetes Association (20)
- eGFR >30 mL/min/1.73 m2 (maximum six months old)
- urine-albumin/creatinine-ratio (uACR) > 700 mg/g or 24 hours urine albumin >700 mg on more than one measurement
Exclusion Criteria:
- Signs of acute kidney failure according to the KDIGO classification (21) at the time for kidney biopsy or the last 6 months before kidney biopsy
Factors that increases the risk of complications due to kidney biopsy:
- Hemoglobin < 6 mmol/L
- INR >1,4 at the time for biopsy
- Platelet count < 100 x 109/l
- Uncontrolled high blood pressure (defined as systolic blood pressure > 160 mmHg and/or diastolic blood pressure > 100 mmHg)
- Only one functioning kidney
- Evidence of urinary tract obstruction or hydronephrosis at the time of biopsy
- Multiple bilateral kidney cysts
- Kidney infection, peri-renal infection, or cutaneous infection that overlies the kidney at time for biopsy
- Unwilling to receive blood transfusion
- Unable to lie flat in bed six hours after biopsy
- Any other contra-indications for percutaneous kidney biopsy according to local clinical guidelines
- Unable to understand written and oral information
- Kidney transplant recipient
- Previous medical kidney biopsy
- Women who are pregnant or planning to become pregnant before the kidney biopsy is performed
- Treatment with Marcoumar (all other anticoagulants are accepted)
High thromboembolic risk combined with held in anticoagulation therapy according to the report "Perioperative regulation of antithrombotic treatment" (PRAB) (22)
- mechanical heart valve
- atrial fibrillation AND CHA2DS2-VASc> 5 and/or stroke within the last three months
- recurrent venous thromboembolism OR venous thromboembolism within the last three months
- less than 6 weeks after uncomplicated Acute Coronary Syndrome (ACS) with or without revascularization (Percutaneous Coronary Intervention (PCI)) with Bare Metal Stents (BMS) or Coronary Artery Bypass Grafting (CABG))
- less than 3 months after uncomplicated ACS with revascularization (PCI with Drug Eluting Stent (DES))
- less than 9-12 months after complicated ACS (e.g. reinfarction or stent thrombosis)
- less than 1 month after revascularization in individuals with stable Coronary Artery Disease (CAD) (PCI with BMS or CABG)
- less than 3 months after revascularization in individuals with stable CAD (PCI with DES)
- less than 3 months after stroke, or Transient Ischemic Attack (TIA)
- Inability to withdraw nonsteroidal anti-inflammatory drugs (NSAID) 7 days before biopsy
If a participant meets one or more exclusion criteria, that are reversible, the participant can be rescreened later on, to evaluate whether or not the participant now is qualified for participation.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Peolpe with T2DM and albuminuria
Prospectively we will collect research kidney biopsies and other biomarkers from blood, faeces, urine, proteomic- and metabolomic profiles and DNA-variants.
The biopsies will be thoroughly investigated with cutting-edge molecular technologies and associated to the biomarkers, disease course and clinical outcome.
|
Harvesting of kidney tissue from people with type 2 diabetes and albuminuria for subsequent analysis
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Prevalence
Time Frame: From baseline to end inclusion (3 years)
|
To investigate the prevalence of biopsy-proven diabetic nephropathy in individuals with T2DM with severe albuminuria; urine albumin/creatinine ratio (UACR) >700 mg/g.
|
From baseline to end inclusion (3 years)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Improved clinical diagnosis
Time Frame: From baseline to end inclusion (3 years)
|
To investigate whether clinical variables, transcriptomic, proteomic and/or metabolomic profiles as well as genetic variation can predict the presence of diabetic nephropathy in a kidney biopsy.
|
From baseline to end inclusion (3 years)
|
diabetic retinopathy
Time Frame: From baseline to end inclusion (3 years)
|
To describe the sensitivity and specificity of diabetic retinopathy in predicting biopsy-proven diabetic nephropathy
|
From baseline to end inclusion (3 years)
|
Kidney Biopsy
Time Frame: From baseline to end of followup (20 years)
|
describe the prognostic value of different histological and molecular findings on kidney biopsy in individuals with biopsy-proven diabetic nephropathy
|
From baseline to end of followup (20 years)
|
non-diabetic nephropathy vs. biopsy-proven diabetic nephropathy
Time Frame: From baseline to end of followup (20 years)
|
describe the prognostic value of different histological and molecular findings on the kidney biopsy in individuals with non-diabetic nephropathy compared to biopsy-proven diabetic nephropathy.
|
From baseline to end of followup (20 years)
|
proteomic and metabolomic
Time Frame: From baseline to end of followup (20 years)
|
describe the prognostic value of the proteomic and metabolomic profiles in biopsy-proven diabetic nephropathy.
|
From baseline to end of followup (20 years)
|
genetic variants
Time Frame: From baseline to end of followup (20 years)
|
describe the prognostic value of different forms of genetic variation in biopsy-proven diabetic nephropathy
|
From baseline to end of followup (20 years)
|
Microbiome
Time Frame: From baseline to end of followup (20 years)
|
describe the prognostic value of different compositions of the microbiome and its relation to biopsy and clinical findings
|
From baseline to end of followup (20 years)
|
Annual changes in kidney status
Time Frame: From baseline to end of followup (20 years)
|
Annual changes in kidney status (defined by yes/no: initiation of dialysis, kidney transplantation, renal death or decrease in eGFR > 40 % compared to eGFR at baseline)
|
From baseline to end of followup (20 years)
|
Annual decline in eGRF
Time Frame: From baseline to end of followup (20 years)
|
Annual decline in eGRF
|
From baseline to end of followup (20 years)
|
Annual changes in albuminuria.
Time Frame: From baseline to end of followup (20 years)
|
Annual changes in albuminuria.
|
From baseline to end of followup (20 years)
|
Annual events of cardiovascular disease
Time Frame: From baseline to end of followup (20 years)
|
Events of cardiovascular disease (fatal CV events, non-fatal stroke, non-fatal myocardial infarction, hospitalization for heart failure, PCI or bypass surgery (heart or legs), amputations due to ischemia, and unstable angina)
|
From baseline to end of followup (20 years)
|
Death
Time Frame: From baseline to end of followup (20 years)
|
Death (any cause).
|
From baseline to end of followup (20 years)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Frederik Persson, MD, PhD, Steno Diabetes Center Copenhagen
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Glucose Metabolism Disorders
- Metabolic Diseases
- Urologic Diseases
- Urological Manifestations
- Endocrine System Diseases
- Disease Attributes
- Diabetes Complications
- Renal Insufficiency
- Urination Disorders
- Proteinuria
- Chronic Disease
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Kidney Diseases
- Renal Insufficiency, Chronic
- Diabetic Nephropathies
- Albuminuria
Other Study ID Numbers
- PRIMETIME2
- H-20080050 (Other Identifier: National Ethical Committee)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Kidney Diseases
-
3-C Institute for Social DevelopmentUniversity of North Carolina, Chapel HillCompletedChronic Kidney Diseases | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Pediatric Kidney Disease | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage V | Chronic Kidney Disease, Stage IV (Severe) | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease, Stage IUnited States
-
Universiti Putra MalaysiaRecruitingChronic Kidney Diseases | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Chronic Kidney Disease stage3 | Chronic Kidney Disease Requiring Chronic DialysisMalaysia
-
American Academy of Family PhysiciansUniversity of Colorado, Denver; National Institute of Diabetes and Digestive... and other collaboratorsCompletedChronic Kidney Disease | Chronic Renal Insufficiency | Chronic Kidney Insufficiency | Chronic Renal Diseases | Kidney Insufficiency, ChronicUnited States
-
Centre Hospitalier le MansLe Mans UniversiteWithdrawnFatigue | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage3 | Chronic Kidney Failure | Chronic Kidney Disease, Stage 4 (Severe)
-
National Taiwan University HospitalCompletedChronic Kidney Disease stage4 | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease Stage 1Taiwan
-
Centre Hospitalier le MansLe Mans UniversiteRecruitingFatigue | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Chronic Kidney Disease Stage 3BFrance
-
University of WashingtonJohns Hopkins University; National Institute of Diabetes and Digestive and... and other collaboratorsRecruitingChronic Kidney Diseases | Acute Renal Failure | Acute Renal Injury | Acute Kidney Failure | Chronic Renal Insufficiency | Kidney Failure, Acute | Renal Insufficiency, Acute | Acute Renal Insufficiency | Acute Kidney Insufficiency | Renal Failure, Acute | Chronic Kidney Insufficiency | Chronic Renal Diseases | Kidney... and other conditionsUnited States
-
Texas A&M UniversityWithdrawnChronic Kidney FailureUnited States
-
University of the State of Santa CatarinaUnknownKidney Diseases | Chronic Kidney Diseases | Hemodialysis | Chronic Renal Insufficiency | Renal Dialysis | Chronic Kidney Insufficiency | Chronic Renal DiseasesBrazil
-
Lund UniversityBaxter Healthcare Corporation; Universidad de CórdobaCompletedEnd Stage Kidney Disease | Chronic Kidney Disease Requiring Chronic DialysisArgentina
Clinical Trials on Kidney Biopsy
-
University of MichiganNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); The...RecruitingGlomerulosclerosis, Focal Segmental | Membranous Nephropathy | Minimal Change Disease (MCD)United States, Canada
-
Weill Medical College of Cornell UniversityQatar National Research FundSuspendedKidney TransplantationUnited States
-
CHU de ReimsUnknownHenoch Schönlein NephritisFrance
-
National Institute of Allergy and Infectious Diseases...CompletedKidney TransplantationUnited States, Australia
-
Andriy TrailinCompletedKidney Graft DysfunctionUkraine
-
University of WashingtonJohns Hopkins University; National Institute of Diabetes and Digestive and... and other collaboratorsRecruitingChronic Kidney Diseases | Acute Renal Failure | Acute Renal Injury | Acute Kidney Failure | Chronic Renal Insufficiency | Kidney Failure, Acute | Renal Insufficiency, Acute | Acute Renal Insufficiency | Acute Kidney Insufficiency | Renal Failure, Acute | Chronic Kidney Insufficiency | Chronic Renal Diseases | Kidney... and other conditionsUnited States
-
University of ManitobaCanadian Institutes of Health Research (CIHR); Canadian National Transplant...RecruitingKidney Transplant; Complications | Rejection of Renal TransplantAustralia, Canada
-
Simeone Andrulli, MDCompletedKidney DiseasesItaly
-
Karolinska InstitutetUniversité Catholique de LouvainRecruitingLupus NephritisSweden
-
Seoul National University HospitalSeoul National University Bundang Hospital; Chung-Ang University Hosptial,... and other collaboratorsRecruitingLupus Nephritis | Focal Segmental Glomerulosclerosis | IgA Nephropathy | Glomerular Disease | Minimal Change Disease | Membranous Nephropathy | Crescentic GlomerulonephritisKorea, Republic of